Search research articles
Contact Us
Filters
Showing results (61-70 of 93) with videos related to
Page
of 10
Sort By:
American Journal of Hematology
|
March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma
Geoffrey Shouse, Matthew Matasar, Lu Chen, et al.
British Journal of Haematology
|
January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
Lihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
American Journal of Hematology
|
December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2017
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab
Matthew G Mei, Thai M Cao, Lu Chen, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 93) with videos related to
Sort By:
Page
of 10
American Journal of Hematology
|
March 18, 2026
Polatuzumab Vedotin Combined With R-ICE (PolaR-ICE) as Second-Line Therapy in Diffuse Large B-Cell Lymphoma
Geoffrey Shouse, Matthew Matasar, Lu Chen, et al.
British Journal of Haematology
|
January 30, 2013
A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma
Lihua E Budde, Michelle M Zhang, Andrei R Shustov, et al.
Blood Advances
|
February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformation
Katharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
The Lancet. Oncology
|
July 8, 2022
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
Lihua E Budde, Laurie H Sehn, Matthew Matasar, et al.
American Journal of Hematology
|
December 23, 2024
Outcomes of CD19 CAR T in Transformed Indolent Lymphoma Compared to De Novo Aggressive Large B-Cell Lymphoma
Swetha Kambhampati Thiruvengadam, Reid Merryman, Yan Wang, et al.
Blood Advances
|
November 21, 2024
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
Elise A Chong, Elicia Penuel, Ellen B Napier, et al.
Blood
|
October 24, 2024
Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies
Laurie H Sehn, Nancy L Bartlett, Matthew J Matasar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 28, 2024
Durable Responses With Mosunetuzumab in Relapsed/Refractory Indolent and Aggressive B-Cell Non-Hodgkin Lymphomas: Extended Follow-Up of a Phase I/II Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 16, 2021
Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study
Lihua E Budde, Sarit Assouline, Laurie H Sehn, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation
|
July 23, 2017
Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab
Matthew G Mei, Thai M Cao, Lu Chen, et al.
Page
of 10